Pasar al contenido principal

ACTIVACION DE PPAR ALFA, RECEPTOR BETA3-ADRENERGICO Y ACE/ANG(1-7)/MAS COMO DIANAS TERAPEUTICAS DEL HIGADO GRASO: UN PROYECTO DE REPOSICIONAMIENTO Y COMBINACION FARMACOLOGICA.

PID2020-112870RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Adipose tissue protects against hepatic steatosis in male rats fed a high-fat diet plus liquid fructose: Sex-related differences

  • Bentanachs, Roger
  • Blanco, Laia
  • Montesinos, Maria
  • Sala Vila, Aleix
  • Lázaro, Iolanda
  • Rodríguez-Morató, Jose, 1987-
  • Sánchez, Rosa María
  • Laguna, Juan Carlos
  • Roglans i Ribas, Núria
  • Alegret i Jordà, Marta
Non-alcoholic fatty liver disease is a sexual dimorphic disease, with adipose tissue playing an essential role. Our previous work showed that female rats fed a high-fat high-fructose diet devoid of cholesterol (HFHFr) developed simple hepatic steatosis dissociated from obesity. This study assessed the impact of the HFHFr diet on the male rat metabolism compared with data obtained for female rats. A total of 16 Sprague Dawley (SD) male rats were fed either a control (standard rodent chow and water) or HFHFr (high-fat diet devoid of cholesterol, plus 10% fructose in drinking water) diet for 3 months. Unlike female rats, and despite similar increases in energy consumption, HFHFr males showed increased adiposity and hyperleptinemia. The expression of hormone-sensitive lipase in the subcutaneous white adipose tissue was enhanced, leading to high free fatty acid and glycerol serum levels. HFHFr males presented hypertriglyceridemia, but not hepatic steatosis, partially due to enhanced liver PPARα-related fatty acid β-oxidation and the VLDL-promoting effect of leptin. In conclusion, the SD rats showed a sex-related dimorphic response to the HFHFr diet. Contrary to previous results for HFHFr female rats, the male rats were able to expand the adipose tissue, increase fatty acid catabolism, or export it as VLDL, avoiding liver lipid deposition., This research was funded by the following grants: SAF2017-82369-R, funded by MCIN/AEI/10.13039/501100011033/ and FEDER, “A Way of Making Europe”; PID2020-112870RB-I00, funded by MCIN/AEI/10.13039/501100011033/; and 2021SGR-00345, funded by Generalitat de Catalunya. R.B. is a predoctoral fellow, funded by PREDOCS-UB from the University of Barcelona.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

KHK, PNPLA3 and PPAR as novel targets for the anti-steatotic action of bempedoic acid

  • Velázquez, Ana Magdalena
  • Bentanachs, Roger
  • Sala Vila, Aleix
  • Lázaro, Iolanda
  • Rodríguez-Morató, Jose, 1987-
  • Sánchez, Rosa María
  • Laguna, Juan Carlos
  • Roglans i Ribas, Núria
  • Alegret i Jordà, Marta
Bempedoic acid (BemA) is an ATP-citrate lyase (ACLY) inhibitor used to treat hypercholesterolemia. We studied the anti-steatotic effect of BemA, and the mechanisms involved, in a model of fatty liver in female rats obtained through the administration of a high-fat diet supplemented with liquid fructose (HFHFr) for three months. In the third month, a group of rats was treated with BemA (30 mg/kg/day) by gavage. Plasma analytes, liver histology, adiposity, and the expression of key genes controlling fatty acid metabolism were determined, and PPAR agonism was explored by using luciferase reporter assays. Our results showed that, compared to HFHFr, BemA-treated rats exhibited lower body weight, higher liver/body weight, and reduced hepatic steatosis. In addition to ACLY inhibition, we found three novel mechanisms that could account for the anti-steatotic effect: (1) reduction of liver ketohexokinase, leading to lower fructose intake and reduced de novo lipogenesis; (2) increased expression of patatin-like phospholipase domain-containing protein 3, a protein related to the export of liver triglycerides to blood; and (3) PPARα agonist activity, leading to increased hepatic fatty acid β-oxidation. In conclusion, BemA may represent a novel approach to treat hepatic steatosis, and therefore to avoid progression to advanced stages of non-alcoholic fatty liver disease., This research was supported by grant SAF2017-82369-R funded by MCIN/AEI/10.13039/501100011033 and by ERDF “A way of making Europe”, grant PID2020-112870RB-I00 funded by MCIN/AEI/10.13039/501100011033, grant 2017 SGR 38 from Generalitat de Catalunya, and Basic Research 2020 grant of the Spanish Atherosclerosis Society. A.M.V. and R.B are predoctoral fellows (BECAL program BCAL04-327, from the Government of Paraguay, and PREDOCS-UB, from the University of Barcelona, respectively). A.S.-V. is a recipient of the Instituto de Salud Carlos III Miguel Servet fellowship (grant CP II 17/00029).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mirabegron induces selective changes in the faecal microbiota of HFHFr rats without altering bile acid composition

  • Bentanachs, Roger
  • Miró, Lluïsa
  • Ramírez-Carrasco, Patricia
  • Sánchez, Rosa M.
  • Bernabeu, Manuel
  • Amat, Concepció
  • Alegret, Marta
  • Pérez-Bosque, Anna
  • Roglans, Núria
  • Laguna, Juan C.
Metabolic dysfunction-associated steatotic liver (MASL), the initial, asymptomatic stage of the metabolic dysfunction-associated steatotic liver disease, is directly involved in the progression to steatohepatitis. Healthy lifestyle and dietary measures are currently the only treatments for MASL. Given the high prevalence of MASL in the human population, candidate drugs for its prevention or treatment should have an acceptable safety profile. Repurposing drugs already in clinical use could help to identify effective and safe drug treatments for MASL. We have characterized a high-fat, high-fructose rat dietary model of simple hepatic steatosis to evaluate the potential anti-steatotic effect of mirabegron, which is already in clinical use for the treatment of overactive bladder. We have previously reported that mirabegron administration was unable to reduce liver triglyceride content in our rat model., The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the following grants: PID2023-146140OB-I00, funded by MICIU/AEI /10.13039/501100011033 and FEDER, PID2020-112870RB-I00, funded by MCIN/AEI/10.13039/501100011033/; 2021SGR-00345 and 2021SGR-00300, funded by Generalitat de Catalunya. RB is a predoctoral fellow, funded by PREDOCS-UB from the University of Barcelona. INSA-UB is recognized as a Maria de Maeztu Unit of Excellence and funded by MICIN/AEI/FEDER (CEX2021-001234-M). MB thanks to the post-PhD grant “Juan de la Cierva” (ref. JDC2022-050269-I) MCIU/AEI and the European Union “Next-Generation EU”/PRTR., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S), Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

KHK, PNPLA3 and PPAR as novel targets for the anti-steatotic action of bempedoic acid

  • Velázquez, Ana Magdalena
  • Bentanachs, Roger
  • Sala Vila, Aleix
  • Lázaro, Iolanda
  • Rodríguez-Morató, Jose, 1987-
  • Sánchez, Rosa María
  • Laguna, Juan Carlos
  • Roglans i Ribas, Núria
  • Alegret i Jordà, Marta
Bempedoic acid (BemA) is an ATP-citrate lyase (ACLY) inhibitor used to treat hypercholesterolemia. We studied the anti-steatotic effect of BemA, and the mechanisms involved, in a model of fatty liver in female rats obtained through the administration of a high-fat diet supplemented with liquid fructose (HFHFr) for three months. In the third month, a group of rats was treated with BemA (30 mg/kg/day) by gavage. Plasma analytes, liver histology, adiposity, and the expression of key genes controlling fatty acid metabolism were determined, and PPAR agonism was explored by using luciferase reporter assays. Our results showed that, compared to HFHFr, BemA-treated rats exhibited lower body weight, higher liver/body weight, and reduced hepatic steatosis. In addition to ACLY inhibition, we found three novel mechanisms that could account for the anti-steatotic effect: (1) reduction of liver ketohexokinase, leading to lower fructose intake and reduced de novo lipogenesis; (2) increased expression of patatin-like phospholipase domain-containing protein 3, a protein related to the export of liver triglycerides to blood; and (3) PPARα agonist activity, leading to increased hepatic fatty acid β-oxidation. In conclusion, BemA may represent a novel approach to treat hepatic steatosis, and therefore to avoid progression to advanced stages of non-alcoholic fatty liver disease., This research was supported by grant SAF2017-82369-R funded by MCIN/AEI/10.13039/501100011033 and by ERDF “A way of making Europe”, grant PID2020-112870RB-I00 funded by MCIN/AEI/10.13039/501100011033, grant 2017 SGR 38 from Generalitat de Catalunya, and Basic Research 2020 grant of the Spanish Atherosclerosis Society. A.M.V. and R.B are predoctoral fellows (BECAL program BCAL04-327, from the Government of Paraguay, and PREDOCS-UB, from the University of Barcelona, respectively). A.S.-V. is a recipient of the Instituto de Salud Carlos III Miguel Servet fellowship (grant CP II 17/00029).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Adipose tissue protects against hepatic steatosis in male rats fed a high-fat diet plus liquid fructose: Sex-related differences

  • Bentanachs, Roger
  • Blanco, Laia
  • Montesinos, Maria
  • Sala Vila, Aleix
  • Lázaro, Iolanda
  • Rodríguez-Morató, Jose, 1987-
  • Sánchez, Rosa María
  • Laguna, Juan Carlos
  • Roglans i Ribas, Núria
  • Alegret i Jordà, Marta
Non-alcoholic fatty liver disease is a sexual dimorphic disease, with adipose tissue playing an essential role. Our previous work showed that female rats fed a high-fat high-fructose diet devoid of cholesterol (HFHFr) developed simple hepatic steatosis dissociated from obesity. This study assessed the impact of the HFHFr diet on the male rat metabolism compared with data obtained for female rats. A total of 16 Sprague Dawley (SD) male rats were fed either a control (standard rodent chow and water) or HFHFr (high-fat diet devoid of cholesterol, plus 10% fructose in drinking water) diet for 3 months. Unlike female rats, and despite similar increases in energy consumption, HFHFr males showed increased adiposity and hyperleptinemia. The expression of hormone-sensitive lipase in the subcutaneous white adipose tissue was enhanced, leading to high free fatty acid and glycerol serum levels. HFHFr males presented hypertriglyceridemia, but not hepatic steatosis, partially due to enhanced liver PPARα-related fatty acid β-oxidation and the VLDL-promoting effect of leptin. In conclusion, the SD rats showed a sex-related dimorphic response to the HFHFr diet. Contrary to previous results for HFHFr female rats, the male rats were able to expand the adipose tissue, increase fatty acid catabolism, or export it as VLDL, avoiding liver lipid deposition., This research was funded by the following grants: SAF2017-82369-R, funded by MCIN/AEI/10.13039/501100011033/ and FEDER, “A Way of Making Europe”; PID2020-112870RB-I00, funded by MCIN/AEI/10.13039/501100011033/; and 2021SGR-00345, funded by Generalitat de Catalunya. R.B. is a predoctoral fellow, funded by PREDOCS-UB from the University of Barcelona.